Medical Licensing (MD/DO) · Independent exam preparation
UEMS EBSQ Examination in Endocrine Surgery: Clinical Decisions and Viva Preparation Study Guide
Practise endocrine surgical decisions, interpret hormone tests, plan safe operations and appraise evidence for the full UEMS EBSQ Endocrine Surgery examination.
By CertMedbry · Updated 19 October 2026
Build defensible decisions about endocrine diagnosis, operative indications, surgical extent and urgent complications. These 60 selected concepts connect biochemical mechanisms with clinical cases across the full Endocrine Surgery pathway. Use them alongside the official Syllabus V05 and Curriculum V04, which define the full scope, including subjects beyond this selective guide. Practise explaining your reasoning, alternatives and follow-up aloud.
Try 20 free practice questionsWhat is the exam format?
Check the question types, timing and outline before planning your revision.
Which examination pathway does this guide cover?
The full Endocrine Surgery examination, covering thyroid, parathyroid, adrenal and endocrine abdominal surgery. UEMS also offers Neck Endocrine Surgery and Neck Endocrine and Adrenal Surgery pathways with narrower scopes. These are separate pathways, rather than historical names for the full examination.
Endocrine Surgery — UEMS Section of Surgery · Endocrine Surgery EBSQ Examinations
What are the assessment format, duration and language?
The examination comprises two English-language viva voce sessions lasting 50–60 minutes each, with two examiners per session. Assessment includes clinical management cases, basic science discussed within those cases, and discussion of two scientific papers supplied about two weeks beforehand. The announced next sitting is in Madrid; the published format is an oral examination rather than an adaptive computer test.
How many questions are asked, and are there scored or pretest items?
The issuer does not publish a fixed number of clinical questions or cases, a scored/pretest item split, or a numerical passing score on its examination page. Two scientific papers are specified. This guide's 20 four-option questions are independent learning drills, not the examination's item format.
Which outline applies, and are effective dates or topic weights published?
The issuer currently links Endocrine Surgery Syllabus V05 and Curriculum V04. Neither document states an explicit issue/effective date or numerical topic weights. Syllabus V04 is historical; Curriculum V04 remains current. Website directory dates are not effective dates. The official documents define the full scope; this guide selects concepts across the domains. Scientific-paper appraisal maps to the paper-discussion component rather than a separately weighted syllabus chapter.
Endocrine Surgery Syllabus and Curriculum · UEMS EBSQ Endocrine Surgery Syllabus V05 · UEMS EBSQ Endocrine Surgery Curriculum V04
What qualification and eligibility process are involved?
Successful eligibility assessment, Part I, followed by examination, Part II, leads to FEBS in Endocrine Surgery. Applicants require specialist surgical certification or an accepted equivalent, documented endocrine surgical training, procedure and competence logbooks, and the other specified portfolio evidence. Additional recommendations apply to applicants trained outside EU/UEMS countries. The fellowship does not automatically confer national recognition or a right to practise; national authorities determine these.
What sitting and application dates are currently announced?
As of 19 October 2026, the issuer announces 20 May 2027 in Madrid, Spain, with applications opening on 1 December and an application deadline of 15 January 2027. All candidates apply through the designated QuizOne platform. Places are limited; the selection Priority Score does not affect examination results.
What fees are published for this examination?
The published total is €1,000 for applicants who have been ESES members for at least the two preceding years: €350 eligibility and €650 examination. The total for other applicants is €1,200: €420 eligibility and €780 examination. The issuer also publishes separate resit, transfer and cancellation conditions. Confirm the applicable conditions when applying.
This guide addresses specialist endocrine surgical reasoning across the full Endocrine Surgery pathway. Its original MCQs and flashcards support learning; they do not reproduce the viva examination or predict a pass.
Outline used: Current issuer-linked Endocrine Surgery Syllabus V05 and Curriculum V04, checked on 2026-10-10. Neither document states an explicit issue or effective date; version identifiers come from their filenames. The assigned workbook label maps to the UEMS EBSQ Examination in Endocrine Surgery, leading to FEBS in Endocrine Surgery. The assigned slug is preserved.
60 key concepts: understand, apply and avoid the traps
Work through the questions by exam domain. Explain the answer in your own words, try the example, then check the common pitfall.
Thyroidnot stated
1.How does TSH determine the first investigation of a thyroid nodule?
TSH links structural assessment to thyroid function. A suppressed TSH raises the possibility of an autonomously functioning nodule, so scintigraphy can establish whether the nodule produces hormone independently. Ultrasound still assesses the remaining gland and cervical nodes. A concordant hyperfunctioning nodule generally does not require routine cytological assessment, whereas nonfunctioning nodules are assessed using ultrasound risk and size. Normal thyroid hormone concentrations do not exclude autonomy when TSH is suppressed.
Apply it
A patient has a 24 mm thyroid nodule, suppressed TSH and normal free thyroxine. Arrange scintigraphy to assess autonomy, while using ultrasound to identify other nodules or lymph nodes requiring separate investigation.
Common pitfall: Sending every large nodule directly for aspiration ignores functional status. Suppressed TSH changes the diagnostic pathway even when free thyroid hormone levels remain normal.
2023 European Thyroid Association Clinical Practice Guidelines for Thyroid Nodule Management
2.Which ultrasound findings and size thresholds support thyroid nodule aspiration?
EU-TIRADS combines sonographic pattern with size rather than treating diameter as the sole indication for aspiration. High-risk features include marked hypoechogenicity, irregular shape or margins, and microcalcifications. The 2023 ETA guideline generally recommends aspiration above 10 mm for EU-TIRADS 5, above 15 mm for EU-TIRADS 4, and above 20 mm for EU-TIRADS 3. Suspicious lymph nodes or suspected extrathyroidal extension can justify investigation below ordinary nodule thresholds.
Apply it
An 18 mm mildly hypoechoic, smooth, oval nodule without high-risk features is EU-TIRADS 4 and exceeds its aspiration threshold. A similarly sized spongiform nodule follows a different pathway despite having the same diameter.
Common pitfall: Applying one universal size cutoff erases risk stratification. Conversely, a small suspicious nodule with abnormal nodes should not be dismissed solely because of its size.
2023 European Thyroid Association Clinical Practice Guidelines for Thyroid Nodule Management
3.How should suspicious cervical lymph nodes change thyroid assessment?
Cervical nodal disease can alter diagnosis and operative planning even when the thyroid primary is small. Cystic change, microcalcifications, abnormal vascularity and loss of normal architecture raise suspicion. Targeted ultrasound-guided aspiration assesses the node; thyroglobulin washout can support thyroid follicular-cell origin when appropriate. Establishing the involved compartment before surgery helps distinguish a therapeutic compartment dissection from unnecessary prophylactic surgery. Interpretation must account for the clinical setting and possible assay contamination.
Apply it
A patient with a small suspicious thyroid nodule also has a cystic lateral neck node. Investigate the node directly and map cervical compartments before proposing thyroid surgery, because nodal confirmation changes the operative discussion.
Common pitfall: Sampling only the thyroid nodule can miss the finding that changes surgical extent. A cystic lateral neck mass in an adult is not automatically benign.
2023 European Thyroid Association Clinical Practice Guidelines for Thyroid Nodule Management · 2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer
4.What should follow a nondiagnostic thyroid aspirate?
A nondiagnostic aspirate indicates inadequate material, not a benign diagnosis. Repeat ultrasound-guided aspiration, ideally with attention to sampling technique and adequacy, is generally the next step. Persistent inadequacy requires integration of ultrasound risk, clinical features and available alternatives, including core biopsy in selected circumstances or diagnostic surgery. A repeatedly nondiagnostic high-risk solid nodule deserves a different response from an uncomplicated predominantly cystic low-risk lesion with stable imaging.
Apply it
A solid 19 mm nodule with irregular margins yields insufficient cells. Repeat targeted ultrasound-guided aspiration rather than reassuring the patient. If sampling remains inadequate, discuss further tissue assessment or diagnostic surgery using the persistent imaging concern.
Common pitfall: Treating an insufficient sample as reassuring substitutes absence of evidence for benignity. Repeated aspiration without reconsidering persistent high-risk imaging can also delay diagnosis.
2023 European Thyroid Association Clinical Practice Guidelines for Thyroid Nodule Management
5.Why can cytology not reliably distinguish follicular adenoma from carcinoma?
Follicular carcinoma is defined by capsular or vascular invasion, features requiring assessment of tissue architecture rather than isolated aspirated cells. A follicular-pattern cytological result therefore describes a diagnostic category rather than proving carcinoma. Management integrates ultrasound risk, clinical factors, molecular testing where validated and available, and the value of diagnostic lobectomy. The key distinction is between estimating malignancy probability before surgery and establishing invasive behaviour on the resected specimen.
Apply it
A patient has a solitary follicular-pattern indeterminate nodule without suspicious nodes. Explain why the aspirate cannot show capsular invasion, then discuss diagnostic lobectomy or other justified risk-refining options within the patient's clinical context.
Common pitfall: Calling every follicular-pattern aspirate cancer can trigger excessive surgery. Calling it benign is equally unsound because cytology cannot assess the invasion defining follicular carcinoma.
2023 European Thyroid Association Clinical Practice Guidelines for Thyroid Nodule Management
6.When should a benign thyroid nodule be reassessed?
Benign cytology must remain concordant with ultrasound and the clinical course. New suspicious features, meaningful growth or symptoms can justify reassessment; growth alone is not synonymous with malignancy. A commonly used significant-growth definition is at least 20% enlargement in two diameters with a minimum 2 mm increase, or more than 50% volume increase. Repeat sampling is particularly relevant when a high-risk ultrasound pattern conflicts with an initially benign cytological result.
Apply it
A previously benign nodule enlarges from 20 × 15 mm to 25 × 19 mm and develops irregular margins. Reassess imaging–cytology concordance and consider repeat aspiration, rather than attributing the change to size alone.
Common pitfall: Small measurement differences can reflect observer variation. The opposite error is allowing an old benign result to override newly suspicious morphology or progressive symptoms.
2023 European Thyroid Association Clinical Practice Guidelines for Thyroid Nodule Management
7.When can benign thyroid disease justify surgery?
Surgical indications extend beyond malignancy. A benign nodule or multinodular goitre may cause compression, dysphagia, airway symptoms, significant cosmetic burden or mediastinal extension. The decision balances attributable symptoms, functional status, anatomical extent and alternatives such as radioiodine or image-guided ablation in suitable patients. Cross-sectional imaging helps define substernal anatomy when needed. A reassuring aspirate addresses malignancy probability but does not resolve a mechanical problem caused by an enlarging gland.
Apply it
A patient with repeatedly benign cytology develops positional breathlessness and progressive dysphagia from a large goitre. Assess airway and substernal anatomy, then discuss definitive treatment based on compression rather than repeating aspiration without a new diagnostic reason.
Common pitfall: Assuming benign cytology rules out a surgical indication overlooks mechanical disease. Conversely, nonspecific throat symptoms require assessment before they are attributed to a small incidental nodule.
2023 European Thyroid Association Clinical Practice Guidelines for Thyroid Nodule Management
8.When is lobectomy appropriate for differentiated thyroid cancer?
For appropriately selected differentiated thyroid cancers, removing one lobe can provide adequate treatment while reducing bilateral surgical exposure. The 2025 ATA guideline favours lobectomy for cancers no larger than 2 cm without gross extrathyroidal extension or clinical nodal or distant metastases, unless bilateral disease or another indication supports total thyroidectomy. Selection also considers histology, contralateral findings and patient preference. Tumour size must be interpreted alongside invasion and metastatic status rather than in isolation.
Apply it
A patient has a 14 mm unilateral papillary carcinoma, no gross extrathyroidal extension and no suspicious cervical nodes. Discuss lobectomy as an appropriate operation, incorporating contralateral ultrasound findings, personal priorities and the implications for subsequent surveillance.
Common pitfall: Equating every thyroid cancer diagnosis with total thyroidectomy ignores risk-adapted surgery. Small size alone also cannot neutralize gross invasion or clinically evident metastases.
9.Which differentiated thyroid cancers favour total thyroidectomy?
Total thyroidectomy is generally indicated for differentiated thyroid cancer larger than 4 cm, gross extrathyroidal extension, clinically apparent nodal metastases or distant metastases, unless contraindications require a modified approach. The operation removes bilateral thyroid tissue and can facilitate radioiodine treatment and biochemical surveillance when these are appropriate. Intermediate situations require individualized discussion. The oncological objective must be balanced against recurrent laryngeal nerve injury, hypoparathyroidism and the patient's ability to tolerate the proposed procedure.
Apply it
A patient has a 48 mm differentiated thyroid carcinoma with clear gross extrathyroidal extension on assessment. Plan comprehensive staging and an oncologically appropriate operation, discussing total thyroidectomy and any indicated therapeutic nodal surgery with the patient.
Common pitfall: Choosing lobectomy from tumour diameter alone can undertreat invasive disease. Conversely, anticipated surveillance convenience should not automatically justify bilateral surgery for every low-risk cancer.
10.When should completion thyroidectomy follow an initial lobectomy?
Completion thyroidectomy depends on what definitive pathology and staging reveal, rather than occurring automatically whenever cancer is found. It may be appropriate when features would have justified bilateral surgery initially, when residual primary disease needs removal, or when a justified radioiodine strategy requires it. Assess recurrent laryngeal nerve function before operating on the remaining side. Low-risk disease adequately treated by lobectomy can often remain under surveillance without a second operation.
Apply it
After lobectomy, pathology shows a small intrathyroidal differentiated carcinoma with favourable features and no other indication for bilateral surgery. Explain why observation can be reasonable, while reviewing whether any pathological or clinical finding changes that conclusion.
Common pitfall: Using the word carcinoma as the sole trigger for completion surgery ignores risk. Reoperation also requires attention to first-side nerve function and cumulative complications.
11.How should thyroglobulin surveillance differ after lobectomy and total thyroidectomy?
Normal follicular tissue produces thyroglobulin, limiting its specificity after lobectomy. The 2025 ATA guideline does not recommend routine thyroglobulin measurement during initial follow-up after lobectomy. A single measurement 6–12 weeks postoperatively with normal TSH may help identify an unexpectedly elevated result, but no validated cutoff is established; this does not justify routine serial testing. After total thyroidectomy, thyroglobulin supports serial surveillance with or without radioiodine. Interpret it with TSH, residual tissue, treatment history and thyroglobulin antibodies, using consistent assays and complementary neck imaging.
Apply it
Following low-risk cancer lobectomy, prioritize clinical assessment and neck ultrasound rather than scheduling routine serial thyroglobulin. After total thyroidectomy, investigate a rising trend by reviewing TSH, antibodies, assay consistency and imaging before diagnosing recurrence.
Common pitfall: Limited specificity after lobectomy is a reason to avoid routine testing, not simply to interpret repeated results cautiously. A possible single postoperative measurement differs from serial surveillance.
12.Which markers distinguish medullary thyroid carcinoma from differentiated cancer?
Medullary thyroid carcinoma arises from parafollicular C cells, making calcitonin and carcinoembryonic antigen relevant markers rather than thyroglobulin. Baseline concentrations assist staging and later surveillance, while trends and doubling times help characterize progression. All patients with apparently sporadic medullary carcinoma should be offered germline RET testing because hereditary disease may be clinically unsuspected. This diagnosis also prompts assessment for associated endocrine disease before surgery when hereditary status is established or remains unresolved.
Apply it
A thyroid aspirate suggests medullary carcinoma in a patient without a known family history. Obtain calcitonin and carcinoembryonic antigen, arrange germline RET assessment, and ensure associated pheochromocytoma risk is addressed before proceeding to thyroid surgery.
Common pitfall: Monitoring medullary carcinoma with thyroglobulin follows the wrong cell lineage. A negative family history does not reliably exclude a germline RET-associated syndrome.
13.How does nodal mapping guide medullary thyroid cancer surgery?
Medullary thyroid carcinoma often spreads through cervical lymphatic compartments, so operative planning combines ultrasound, disease extent and biochemical burden. Total thyroidectomy with central compartment dissection is recommended for disease without evident distant metastases and without imaging evidence of nodal involvement. Demonstrated lateral nodal disease supports therapeutic dissection of involved compartments. Extending surgery into clinically uninvolved lateral compartments requires careful assessment; a marker concentration alone should not be treated as a universally applicable instruction.
Apply it
A patient with medullary carcinoma has confirmed metastatic nodes in one lateral neck compartment. Map the central and contralateral neck, assess distant disease when indicated, and plan therapeutic compartment surgery rather than removing only the palpable node.
Common pitfall: Isolated node removal can leave disease throughout an involved compartment. The opposite error is indiscriminate bilateral lateral dissection without an adequate disease-specific justification.
14.How should airway-threatening haematoma after thyroid surgery be managed?
Neck haematoma can impair venous drainage and cause progressive laryngeal oedema. Give oxygen and summon senior surgical and anaesthetic help. With airway compromise, decompress immediately at the bedside using SCOOP: Skin exposure; Cut sutures; Open skin; Open muscles; Pack wound. Release the deep closure and strap muscles and evacuate the clot; opening skin alone may leave compression unresolved. Do not delay for imaging or theatre transfer. Persistent compromise requires emergency airway management by experienced clinicians, including tracheal intubation and progression to an emergency front-of-neck airway if oxygenation cannot be achieved. Definitive haemostasis follows stabilization.
Apply it
A patient develops stridor and a tense neck wound two hours after thyroidectomy. Begin SCOOP while help attends, explicitly opening the strap-muscle closure. If breathing does not improve, the experienced airway team must secure oxygenation urgently.
Common pitfall: A functioning drain does not exclude dangerous haematoma. Superficial wound opening is insufficient when deep compression remains, and decompression does not replace airway escalation when compromise persists.
Management of Haematoma Following Thyroid Surgery — Supporting Materials Version 1.0
Parathyroidsnot stated
15.What biochemical pattern establishes hypercalcaemic primary hyperparathyroidism?
Primary hyperparathyroidism is a biochemical diagnosis: elevated adjusted serum calcium with elevated or inappropriately normal PTH on repeated assessment. PTH should normally be suppressed by hypercalcaemia, so a laboratory-normal result can still be abnormal in context. Confirm calcium status, review renal function, vitamin D and relevant medications, and consider alternative explanations such as familial hypocalciuric hypercalcaemia. A neck scan cannot establish the diagnosis because localization describes anatomy rather than autonomous hormone secretion.
Apply it
A patient has repeated hypercalcaemia with PTH in the upper half of the reference interval. Recognize the failure of physiological suppression, review confounders and evaluate primary hyperparathyroidism instead of dismissing the result as a normal PTH.
Common pitfall: Requiring PTH to exceed its reference range misses inappropriate secretion during hypercalcaemia. Ordering localization before establishing the biochemical diagnosis reverses the proper sequence.
16.How does familial hypocalciuric hypercalcaemia differ from primary hyperparathyroidism?
Familial hypocalciuric hypercalcaemia commonly reflects altered calcium sensing, producing lifelong mild hypercalcaemia with relatively low urinary calcium and nonsuppressed PTH. A calcium–creatinine clearance ratio below 0.01 supports suspicion but is not diagnostic because values overlap with primary hyperparathyroidism. Vitamin D deficiency, renal impairment and thiazides complicate interpretation. Family biochemistry, historical calcium results and appropriate genetic testing help resolve uncertainty. Parathyroidectomy usually fails to correct the underlying calcium-sensing abnormality.
Apply it
A young adult has mild hypercalcaemia, a clearance ratio of 0.007 and a parent with similar lifelong results. Check confounders and consider genetic assessment before recommending surgery for an apparent parathyroid lesion on ultrasound.
Common pitfall: Treating a low clearance ratio as definitive overlooks overlap and confounding. Treating an incidental neck lesion as proof of surgically curable disease is equally misleading.
European Expert Consensus on Parathyroid Disorders: PARAT 2021 — published 2022
17.When can elevated PTH with normal calcium represent primary disease?
Normocalcaemic primary hyperparathyroidism requires persistently elevated PTH with consistently normal total and ionized calcium after secondary causes have been excluded. Vitamin D deficiency, inadequate calcium intake, renal impairment, malabsorption, hypercalciuria and medication effects can all produce secondary PTH elevation. Repeated measurements over time prevent premature classification. Correcting a secondary driver may normalize PTH or reveal previously obscured hypercalcaemic disease. Operative decisions require particular caution because evidence and selection criteria are less established.
Apply it
A patient has normal adjusted calcium, elevated PTH and severe vitamin D deficiency. Correct the deficiency and assess intake and renal function before diagnosing normocalcaemic primary hyperparathyroidism or arranging an operation based on localization imaging.
Common pitfall: A single elevated PTH with normal calcium is insufficient. Omitting ionized calcium can also misclassify a patient who actually has hypercalcaemic primary hyperparathyroidism.
European Expert Consensus on Parathyroid Disorders: PARAT 2021 — published 2022 · Evaluation and Management of Primary Hyperparathyroidism: Fifth International Workshop Guidelines — 2022
18.Which skeletal and age findings support parathyroidectomy in asymptomatic disease?
For asymptomatic primary hyperparathyroidism, the Fifth International Workshop identifies objective indications for surgery, including age below 50 years, serum calcium more than 1 mg/dL above the upper reference limit, vertebral fracture or a bone-density T-score of −2.5 or lower at an assessed site. Renal criteria provide additional independent indications. These thresholds identify organ risk even without overt symptoms. Surgery remains an option outside these criteria when the patient and clinician agree and contraindications are absent.
Apply it
A 47-year-old patient has confirmed primary hyperparathyroidism, mild calcium elevation and normal bone density. Explain that age alone meets a workshop surgical criterion, while discussing operative benefits, alternatives and the patient's preferences during shared decision-making.
Common pitfall: Waiting for severe hypercalcaemia or a fracture ignores independent indications. These criteria guide asymptomatic disease and should not obscure clear symptomatic complications requiring treatment.
19.Which renal findings support surgery for primary hyperparathyroidism?
Renal assessment detects complications that symptoms alone may miss. The Fifth International Workshop includes nephrolithiasis or nephrocalcinosis on imaging, estimated filtration or creatinine clearance below 60 mL/min, and hypercalciuria above 250 mg/day in women or 300 mg/day in men among surgical criteria. A complete evaluation integrates renal function, urinary calcium and stone imaging when appropriate. Urinary calcium helps assess risk but must also be interpreted within the differential diagnosis of hypercalcaemia.
Apply it
A woman with confirmed primary hyperparathyroidism reports no renal colic, but imaging shows a renal calculus. Explain that silent stone disease is a renal indication for surgery even if serum calcium elevation is modest and kidney function is preserved.
Common pitfall: Absence of renal pain does not exclude target-organ disease. Using an outdated universal urinary-calcium threshold can also misclassify patients under the current workshop criteria.
20.Why do negative localization studies not exclude parathyroid surgery?
Ultrasound, sestamibi and other localization studies help plan an operation after the biochemical diagnosis and surgical indication are established. They do not determine whether primary hyperparathyroidism exists. Small glands, multigland disease and ectopic locations can produce negative or discordant results. A patient with a valid indication remains a surgical candidate despite nonlocalizing imaging. An experienced surgeon can discuss bilateral exploration or further targeted imaging according to the individual anatomy and operative circumstances.
Apply it
A patient with confirmed primary hyperparathyroidism and recurrent stones has negative ultrasound and sestamibi studies. Continue the surgical evaluation and discuss an exploration strategy rather than telling the patient that an operation is impossible without a positive scan.
Common pitfall: Using localization as a diagnostic gatekeeper denies treatment to suitable patients. Conversely, a positive scan cannot replace biochemical confirmation or exclude a familial calcium disorder.
AAES Guidelines for Definitive Management of Primary Hyperparathyroidism — 2016
21.How is focused parathyroidectomy distinguished from bilateral exploration?
Focused surgery targets a localized abnormal gland when single-gland disease is likely. Bilateral exploration evaluates multiple glands and is particularly relevant when localization is absent or discordant, or multigland disease is suspected. Both approaches can achieve cure in appropriate settings. The decision integrates imaging, familial syndromes, previous surgery and surgeon expertise; intraoperative PTH can provide functional information during a focused approach. A localized lesion is not a guarantee that every other gland is normal.
Apply it
A patient has concordant localization of one lesion and no evidence suggesting hereditary or multigland disease. Discuss focused surgery with appropriate intraoperative assessment, while explaining circumstances that could require extending the exploration during the same operation.
Common pitfall: Insisting on a small incision despite evidence of additional hypersecreting tissue prioritizes access over cure. Bilateral exploration is also not automatically required for every localized case.
AAES Guidelines for Definitive Management of Primary Hyperparathyroidism — 2016
22.How does intraoperative PTH help assess parathyroid resection?
PTH has a short circulating half-life, so its decline after excision provides rapid evidence that hypersecreting tissue has been removed. One named protocol is the Miami criterion: obtain preincision and pre-excision samples, then assess whether PTH has fallen by at least 50% from the higher baseline concentration at 10 minutes after excision. This is a specific protocol; institutional alternatives may use different sampling times or additional requirements. The criterion is described in the [primary comparison study abstract](https://pubmed.ncbi.nlm.nih.gov/14668730/).
Apply it
Suppose preincision PTH is 120 pg/mL, pre-excision PTH is 180 pg/mL and the 10-minute value is 70 pg/mL. Use 180 as the baseline: the decline is (180 − 70)/180 × 100 = 61.1%, meeting the Miami criterion. A value of 110 pg/mL represents only a 38.9% decline. If the criterion is unmet, verify sampling times and specimen handling, consider an additional delayed sample under the operative protocol, and reassess for remaining hyperfunctioning tissue before deciding whether further exploration is needed.
Common pitfall: Using the lower baseline or an incorrectly timed sample can change the interpretation. An inadequate decline warrants reassessment rather than automatic closure or indiscriminate additional resection. A satisfactory decline predicts operative success but does not establish durable cure: postoperative calcium assessment must confirm sustained normocalcaemia, including assessment beyond six months.
AAES Guidelines for Definitive Management of Primary Hyperparathyroidism — 2016
23.How can hungry bone syndrome be distinguished from postoperative hypoparathyroidism?
After removal of a strong PTH stimulus, bone can rapidly take up calcium, phosphate and magnesium, producing hungry bone syndrome. PTH is often preserved or elevated, while phosphate is commonly low. Hypoparathyroidism instead produces low or inappropriately normal PTH with impaired renal phosphate excretion, tending toward higher phosphate. Timing, preoperative bone turnover and serial laboratory results help distinguish them. Both require careful calcium management, but the mechanism predicts replacement needs and the likely duration of recovery.
Apply it
After parathyroidectomy for severe skeletal disease, a patient develops prolonged hypocalcaemia, low phosphate and preserved PTH. Recognize substantial skeletal mineral uptake and plan sustained replacement and monitoring rather than assuming permanent loss of parathyroid function from the operation.
Common pitfall: Labelling all postoperative hypocalcaemia hypoparathyroidism ignores bone uptake. PTH and phosphate provide useful discrimination, although renal impairment and treatment can modify the expected pattern.
European Expert Consensus on Parathyroid Disorders: PARAT 2021 — published 2022
24.When is hyperparathyroidism persistent rather than recurrent after surgery?
Persistent primary hyperparathyroidism means hypercalcaemia continues or returns within six months of surgery; recurrent disease follows a period of normocalcaemia lasting more than six months. An elevated PTH alone does not establish either diagnosis when calcium is normal. Reassessment should confirm biochemistry, review the original diagnosis and operation, and evaluate secondary PTH drivers. Reoperative surgery requires a clearly justified indication and careful localization because scarred anatomy raises nerve and parathyroid injury risks.
Apply it
Eight months after documented normocalcaemia, a patient again has hypercalcaemia with nonsuppressed PTH. Assess recurrent disease, reviewing prior records and excluding confounders before planning localization and any discussion of repeat neck surgery with an experienced team.
Common pitfall: Calling isolated postoperative PTH elevation recurrent disease can prompt unnecessary reoperation. The calcium trajectory and six-month boundary distinguish recurrence from persistence and secondary biochemical changes.
European Expert Consensus on Parathyroid Disorders: PARAT 2021 — published 2022
25.How do secondary and tertiary hyperparathyroidism differ mechanistically?
Secondary hyperparathyroidism is a compensatory response to a sustained stimulus, such as disturbed mineral metabolism in chronic kidney disease. Reduced calcitriol availability, phosphate retention and altered calcium balance promote PTH secretion and gland hyperplasia. Tertiary disease describes persistent autonomous secretion after prolonged secondary stimulation, often with hypercalcaemia despite correction of the original setting. Distinguishing these patterns requires the history and serial calcium, phosphate, renal function and PTH results, rather than interpreting an isolated high PTH.
Apply it
A kidney transplant recipient has persistent hypercalcaemia and markedly elevated PTH after years of renal secondary hyperparathyroidism. Consider autonomous tertiary disease while reviewing graft function, medication effects and the longitudinal mineral profile before discussing treatment with the renal team.
Common pitfall: Any high PTH in a patient with kidney disease is not automatically tertiary disease. Autonomy, calcium status and persistence beyond the original stimulus provide essential distinctions.
UEMS EBSQ Endocrine Surgery Syllabus V05 · European Expert Consensus on Parathyroid Disorders: PARAT 2021 — published 2022
Adrenalsnot stated
26.Which adrenal CT appearance strongly supports a benign adenoma?
A homogeneous adrenal mass measuring 10 Hounsfield units or less on unenhanced CT has imaging characteristics of a lipid-rich benign adenoma. The 2023 ESE guideline recommends no further imaging for such a lesion, irrespective of size, when this characterization is secure. Imaging benignity does not by itself establish absence of hormone secretion. Clinical assessment and appropriate endocrine testing remain separate tasks, with investigation tailored to the lesion's appearance and the patient's circumstances.
Apply it
An incidental 32 mm adrenal lesion is homogeneous and measures 6 HU on an unenhanced scan. Explain why additional imaging surveillance is generally unnecessary for that appearance, while arranging the appropriate assessment of possible hormone excess.
Common pitfall: A low value measured only after contrast is not the unenhanced criterion. Equating a benign radiological appearance with a nonfunctioning lesion also misses a separate question.
ESE Clinical Practice Guidelines on Adrenal Incidentalomas — 2023
27.Which adrenal imaging features increase concern for malignancy?
Adrenal malignancy risk rises when a lesion is heterogeneous, has high unenhanced attenuation, shows invasive features or grows suspiciously. A mass at least 4 cm that is heterogeneous or exceeds 20 HU warrants multidisciplinary discussion, often with surgery considered after staging. Other indeterminate combinations require individualized additional imaging or surveillance. Diameter alone neither establishes carcinoma nor safely excludes it. Imaging interpretation must also consider a known extra-adrenal malignancy and biochemical evidence of hormone secretion.
Apply it
A 56 mm heterogeneous adrenal mass measures 31 HU without contrast. Arrange endocrine assessment, staging and specialist multidisciplinary review rather than applying the benign lipid-rich adenoma pathway or assuming that biopsy is the routine next step.
Common pitfall: Calling every mass above a size cutoff cancer overstates certainty. Conversely, describing all incidental lesions as adenomas ignores attenuation, heterogeneity and evidence of local invasion.
ESE Clinical Practice Guidelines on Adrenal Incidentalomas — 2023
28.How is mild autonomous cortisol secretion assessed in an adrenal incidentaloma?
The overnight 1 mg dexamethasone suppression test assesses whether cortisol secretion suppresses appropriately. In a patient without overt Cushing features, post-test cortisol above 1.8 micrograms/dL, or 50 nmol/L, supports mild autonomous cortisol secretion after confounders are considered and ACTH independence is established. Surgery is not determined by that threshold alone. Associated hypertension, diabetes, age, general health and persistence of autonomy inform an individualized discussion about whether removing a unilateral lesion offers benefit.
Apply it
A patient with a unilateral adrenal mass has post-dexamethasone cortisol of 3.2 micrograms/dL and difficult-to-control diabetes. Confirm the endocrine pattern and evaluate relevant comorbidities before discussing whether adrenalectomy offers sufficient benefit to justify operative risks.
Common pitfall: A result above the suppression threshold is not equivalent to overt Cushing syndrome. Automatically operating on the number ignores confounders, comorbidities and the individualized benefit assessment.
ESE Clinical Practice Guidelines on Adrenal Incidentalomas — 2023
29.Which biochemical tests best assess suspected pheochromocytoma?
Initial biochemical testing uses plasma free metanephrines or urinary fractionated metanephrines because catecholamine metabolism within the tumour can generate these metabolites continuously. Episodic symptoms therefore do not require capturing a spell with a random catecholamine measurement. Sampling conditions, medications and physiological stress affect specificity, particularly for modest elevations. Plasma sampling should follow an appropriate rested, supine protocol where used. Strong biochemical evidence is interpreted with localization imaging and the wider hereditary or clinical context.
Apply it
A patient has episodic headaches, palpitations and an indeterminate adrenal lesion. Obtain appropriately collected metanephrines, reviewing interfering factors, instead of relying on a random catecholamine result obtained between attacks to decide whether pheochromocytoma is present.
Common pitfall: Poor sampling conditions can produce misleading borderline elevations. A normal catecholamine measurement between spells is not an adequate substitute for the recommended metanephrine-based assessment.
Pheochromocytoma and Paraganglioma: Endocrine Society Clinical Practice Guideline — 2014
30.Why must alpha blockade precede beta blockade before pheochromocytoma surgery?
Catecholamine excess causes alpha-mediated vasoconstriction and can contract circulating volume. Preoperative alpha blockade reduces vasoconstrictive responses; salt and fluid measures help restore volume when appropriate. If tachycardia requires beta blockade, it is introduced only after adequate alpha blockade. Starting beta blockade first can leave unopposed alpha-mediated vasoconstriction and provoke severe hypertension. Preparation also includes haemodynamic assessment and coordinated anaesthetic planning because tumour manipulation and removal can produce abrupt blood-pressure changes in opposite directions.
Apply it
A patient with a catecholamine-secreting adrenal tumour has hypertension and tachycardia. Establish alpha blockade and assess volume status before adding a beta blocker if still needed, coordinating the preparation and operative plan with endocrinology and anaesthesia.
Common pitfall: Treating tachycardia first with isolated beta blockade can worsen vasoconstriction. Preoperative preparation also requires attention to volume depletion rather than blood-pressure targets alone.
Pheochromocytoma and Paraganglioma: Endocrine Society Clinical Practice Guideline — 2014
31.How can hypokalaemia distort primary aldosteronism screening?
Primary aldosteronism features inappropriate aldosterone production with suppressed renin, interpreted using both absolute concentrations and their relationship. Hypokalaemia can suppress aldosterone secretion and produce a misleadingly low result. Potassium should therefore be corrected and testing repeated when a negative screen conflicts with substantial clinical suspicion. Medication effects, sodium intake and collection conditions also influence interpretation. A high ratio caused only by extremely low renin is not equivalent to convincing autonomous aldosterone excess.
Apply it
A patient with resistant hypertension has potassium of 2.8 mmol/L and an apparently negative aldosterone screen. Correct the potassium and review test conditions and medications before accepting the result as sufficient to exclude primary aldosteronism.
Common pitfall: Assuming hypokalaemia always amplifies the biochemical signal reverses its effect on aldosterone secretion. Interpreting the ratio without the component values can create another error.
Primary Aldosteronism: An Endocrine Society Clinical Practice Guideline — 2025
32.Why is adrenal venous sampling usually needed before surgery for primary aldosteronism?
Adrenal CT defines anatomy, whereas adrenal venous sampling identifies whether aldosterone excess is unilateral or bilateral. A visible nodule may be nonfunctioning, and an aldosterone-producing lesion may escape CT detection. Most surgical candidates therefore need CT plus technically adequate adrenal venous sampling before adrenalectomy. The 2025 Endocrine Society guideline gives a potential exception: age below 35 years, marked primary aldosteronism with hypokalaemia, and a unilateral adrenal adenoma larger than 1 cm on CT. These combined findings may justify proceeding without sampling after clinical judgment; they do not create an automatic exemption.
Apply it
A 58-year-old with confirmed primary aldosteronism and a left adrenal nodule wants surgery. Arrange adrenal venous sampling to establish lateralization: the nodule alone cannot distinguish unilateral aldosterone production from bilateral disease with an incidental adenoma.
Common pitfall: Neither young age nor hypokalaemia alone establishes the exception. Do not extend it to a patient aged 40 years, a subcentimetre nodule, or an older patient with an incidental adenoma. Removing the largest nodule without functional lateralization risks persistent aldosterone excess.
Primary Aldosteronism: An Endocrine Society Clinical Practice Guideline — 2025
33.Why is glucocorticoid replacement required after surgery for overt adrenal Cushing syndrome?
An autonomous cortisol-producing adrenal lesion suppresses hypothalamic CRH, pituitary ACTH and the function of the remaining adrenal cortex. Removing the lesion abruptly removes the dominant cortisol source before the suppressed axis can recover. Perioperative glucocorticoid coverage and postoperative replacement are therefore required for overt adrenal Cushing syndrome. Subsequent tapering depends on clinical assessment and documented hypothalamic–pituitary–adrenal recovery, rather than a fixed assumption that unilateral surgery always leaves adequate immediate cortisol production.
Apply it
After unilateral adrenalectomy for overt cortisol excess, a patient asks why steroid tablets are necessary when one gland remains. Explain suppression of the remaining gland and arrange replacement, illness education and reassessment of recovery before treatment withdrawal.
Common pitfall: One anatomically intact adrenal does not guarantee immediate physiological reserve. Stopping replacement because the cortisol-producing tumour has been cured can precipitate clinically significant adrenal insufficiency.
34.When is adrenal biopsy appropriate?
The ESE guideline requires three prerequisites before adrenal biopsy is considered: hormonal inactivity, especially biochemical exclusion of pheochromocytoma; imaging that has not conclusively established benignity; and a histological result that would change management. A common setting is suspected metastasis in a patient with extra-adrenal malignancy. Biopsy is not a routine discriminator between cortical adenoma and adrenocortical carcinoma. Establish the complete endocrine assessment and the clinical question, and consider whether another tissue site is safer. Excluding pheochromocytoma addresses a critical sampling hazard but does not alone establish biopsy eligibility.
Apply it
A patient with lung cancer has an indeterminate adrenal lesion whose classification would alter treatment intent. Confirm hormonal inactivity, including exclusion of pheochromocytoma, review whether imaging establishes benignity, and determine exactly how histology would change treatment before arranging biopsy.
Common pitfall: Possible metastasis, FDG uptake or interval growth does not replace hormonal assessment. A negative pheochromocytoma test is one part of the full prerequisites, not the whole assessment.
ESE Clinical Practice Guidelines on Adrenal Incidentalomas — 2023
35.What determines the operative approach to suspected adrenocortical carcinoma?
The operative objective in suspected adrenocortical carcinoma is complete en bloc resection with an intact capsule and clear margins. Tumour rupture or fragmented removal can compromise oncological control. Local invasion, tumour characteristics and the surgeon's expertise determine whether an open approach is required; minimally invasive surgery is reserved for appropriately selected noninvasive lesions. Preoperative assessment includes hormone secretion and staging. Technical convenience must not displace the central requirement for an oncologically complete, non-disruptive resection.
Apply it
A large adrenal tumour appears to invade adjacent structures on imaging. Refer for specialist multidisciplinary planning and an operation capable of en bloc clearance, rather than attempting a limited minimally invasive excision that risks capsule rupture or incomplete margins.
Common pitfall: Choosing access solely by lesion diameter ignores invasion and feasibility of intact resection. A smaller incision offers little benefit if it compromises the cancer operation.
AAES Guidelines for Adrenalectomy: Executive Summary — 2022 · ESE Clinical Practice Guidelines on Adrenal Incidentalomas — 2023
36.Why do pheochromocytoma and paraganglioma require genetic and long-term assessment?
Pheochromocytoma and paraganglioma have important hereditary associations that influence family assessment, surveillance and the likelihood of multifocal disease. Genetic evaluation should be discussed with all affected patients using an informed, clinically guided approach. Histological appearance alone cannot reliably establish absence of metastatic potential; metastases at sites without normal chromaffin tissue establish metastatic disease. Follow-up therefore integrates postoperative biochemical assessment and ongoing surveillance tailored to tumour location, genotype and other risk features over time.
Apply it
A patient has an apparently solitary paraganglioma and no known family history. Discuss genetic evaluation and continued follow-up after treatment, explaining why an unremarkable pedigree or reassuring microscopic appearance does not remove hereditary or later disease risks.
Common pitfall: Calling a tumour permanently benign from histology can provide false reassurance. Restricting genetic discussion to patients with an obvious family history misses clinically important hereditary disease.
Pheochromocytoma and Paraganglioma: Endocrine Society Clinical Practice Guideline — 2014
Diffuse neuroendocrine system of the gastro-entero-pancreatic tractnot stated
37.What establishes endogenous hyperinsulinaemic hypoglycaemia?
Whipple's triad comprises compatible symptoms, documented low plasma glucose during symptoms, and relief when glucose is corrected. During hypoglycaemia, insulin should be suppressed. ENETS Table 4 illustrates glucose below 2.5 mmol/L with insulin above 20.8 pmol/L, C-peptide above 0.2 nmol/L and proinsulin above 5 pmol/L as an inappropriate endogenous secretion pattern. Interpret simultaneous samples with assay characteristics, suppressed beta-hydroxybutyrate and secretagogue testing. Sulfonylureas and meglitinides reproduce this pattern; exogenous insulin usually suppresses C-peptide. Establish the cause before localization.
Apply it
Confusion occurs with laboratory glucose 2.2 mmol/L and resolves after glucose. Simultaneous insulin is 45 pmol/L, C-peptide 0.5 nmol/L, proinsulin 12 pmol/L and beta-hydroxybutyrate 0.4 mmol/L. This supports insulin-mediated endogenous secretion, but a secretagogue screen is needed before attributing it to insulinoma.
Common pitfall: Reference-range insulin can be inappropriate during hypoglycaemia. These values require assay-aware interpretation and do not distinguish insulinoma from secretagogue exposure by themselves.
ENETS 2023 Guidance Paper for Functioning Pancreatic Neuroendocrine Tumour Syndromes
38.Why must gastric acidity accompany interpretation of hypergastrinaemia?
The classic Zollinger–Ellison diagnostic combination is fasting gastrin exceeding ten times the upper reference limit with gastric pH at or below 2, assessed without confounding acid suppression. Gastrin rises appropriately with reduced acidity, including proton-pump inhibitor treatment or atrophic gastritis. Lesser elevations with an acidic stomach require additional confirmation rather than automatic diagnosis; specialist assessment integrates repeat biochemistry, gastric evaluation and appropriate tumour investigation. Acid suppression complicates interpretation, but its withdrawal can cause severe acid-related complications and must follow a supervised specialist plan.
Apply it
Fasting gastrin is 1,500 pg/mL with an upper reference limit of 100 pg/mL, gastric pH is 1.5 and acid suppression is not confounding assessment. The 15-fold elevation with acidity fits the classic combination. A fourfold elevation at the same pH needs further confirmation.
Common pitfall: An undefined 'high gastrin' misses the quantitative discriminator. Even a major elevation during proton-pump inhibitor treatment requires careful interpretation; medication must not be stopped unsupervised.
ENETS 2023 Guidance Paper for Functioning Pancreatic Neuroendocrine Tumour Syndromes
39.How do function, differentiation and grade describe different NET properties?
A functioning neuroendocrine tumour produces a clinical hormone syndrome; immunostaining for a hormone alone does not establish functional disease. Differentiation describes how closely the tumour resembles organized neuroendocrine tissue, while grade reflects proliferative activity, including mitotic rate and Ki-67. These dimensions answer different questions and influence management alongside anatomical stage. A small functioning tumour may require treatment because of dangerous hormone effects, whereas a similarly sized nonfunctioning lesion may qualify for surveillance after careful assessment.
Apply it
A small pancreatic NET stains for insulin, but the patient has no documented hypoglycaemia. Classify clinical function separately from staining, then use grade, stage, anatomy and patient factors to discuss observation or intervention with the multidisciplinary team.
Common pitfall: Calling a tumour functioning solely because of positive immunostaining overstates the clinical syndrome. Treating all well-differentiated tumours as indolent similarly ignores proliferative grade and stage.
NANETS Consensus Paper on Surgical Management of Pancreatic Neuroendocrine Tumors — 2020
40.When can a small nonfunctioning pancreatic NET be observed?
Observation can be reasonable for selected small, asymptomatic nonfunctioning pancreatic NETs because pancreatic surgery carries substantial morbidity. Lesions below 1 cm are particularly suitable for consideration, while those measuring 1–2 cm require individualized assessment. Grade, growth, ductal changes, invasion, nodal findings, age, comorbidity and the feasibility of reliable surveillance influence the decision. Size is a starting point rather than proof of harmlessness. A functioning syndrome or concerning structural feature changes the balance toward intervention.
Apply it
An older patient with significant comorbidity has an incidental 8 mm nonfunctioning pancreatic NET without concerning imaging features. Discuss structured surveillance, including what growth or new findings would trigger reconsideration, rather than presenting pancreatic resection as the only option.
Common pitfall: Observation requires a follow-up plan and a suitable lesion. Applying a small-size rule to a functioning, invasive or duct-obstructing tumour overlooks features that change management.
NANETS Consensus Paper on Surgical Management of Pancreatic Neuroendocrine Tumors — 2020
41.Which pancreatic NETs are suitable for enucleation?
Enucleation preserves pancreatic parenchyma but requires favourable tumour biology and a safe relationship to the main pancreatic duct. Small lesions with low malignant potential, particularly selected insulinomas, may be candidates when sufficiently separated from the duct, commonly by more than 2–3 mm. Deep location, duct proximity, suspected invasion or a need for formal nodal clearance can favour anatomical resection. Parenchymal preservation must be balanced against pancreatic fistula risk and the adequacy of the oncological operation.
Apply it
A small presumed insulinoma lies close to the main pancreatic duct on high-quality imaging. Reassess whether enucleation is safe and discuss alternative surgery rather than selecting parenchymal preservation solely because the tumour is small and apparently localized.
Common pitfall: Small size does not guarantee a safe enucleation plane. Duct injury and inadequate cancer clearance are distinct reasons why a limited operation may be inappropriate.
NANETS Consensus Paper on Surgical Management of Pancreatic Neuroendocrine Tumors — 2020
42.How do anatomical and somatostatin-receptor imaging complement NET staging?
Anatomical imaging defines the primary lesion, vascular relationships, ductal anatomy and sites of spread. Somatostatin-receptor imaging provides complementary whole-body information about receptor-expressing disease and can influence treatment selection. Neither modality answers every question: small lesions or receptor-poor disease may be missed, and avidity does not replace pathological assessment of grade. Operative planning therefore integrates imaging with hormone findings, histology when available and the consequences of any additional lesion for the proposed treatment.
Apply it
A pancreatic NET appears resectable on cross-sectional imaging, but receptor imaging identifies additional suspected deposits. Clarify their significance before finalizing the operation, because occult metastatic disease may change the aim and extent of surgical treatment for the patient.
Common pitfall: Receptor uptake does not establish tumour grade or guarantee that every lesion is a NET. A negative functional scan also cannot erase a convincing anatomical abnormality.
NANETS Consensus Paper on Surgical Management of Pancreatic Neuroendocrine Tumors — 2020
43.When can surgery be considered for metastatic pancreatic NET disease?
Metastatic pancreatic NET management depends on tumour biology, burden, distribution, symptoms and available systemic or liver-directed treatments. Selected patients may benefit from resection or cytoreduction, particularly when meaningful disease clearance or hormone control is feasible at acceptable risk. Evidence for many surgical comparisons is observational and vulnerable to selection bias. Resection of an asymptomatic primary in unresectable metastatic disease is therefore individualized rather than an automatic rule, with attention to future obstruction, bleeding and overall treatment goals.
Apply it
A fit patient has a pancreatic NET and limited liver metastases. Discuss grade, distribution, achievable clearance and hormone symptoms in a multidisciplinary meeting before deciding whether combined surgery offers sufficient benefit compared with other treatments available to the patient.
Common pitfall: Metastases do not automatically eliminate every surgical role. Conversely, favourable survival in selected surgical series does not prove that all patients benefit from primary-tumour resection.
NANETS Consensus Paper on Surgical Management of Pancreatic Neuroendocrine Tumors — 2020
44.Why must the entire small bowel be assessed during NET surgery?
Small-bowel NETs can be tiny and multifocal, so preoperative imaging may underestimate the number and location of primary lesions. Systematic assessment of the entire small bowel, including careful palpation, helps avoid leaving occult primaries behind. Operative planning also addresses regional mesenteric nodal disease while preserving bowel length and vascular supply. A minimally invasive approach must still permit the necessary bowel assessment; the access method should not compromise detection of clinically relevant multifocal disease.
Apply it
Imaging identifies one ileal NET with mesenteric nodes. During surgery, systematically inspect and palpate the full small bowel before determining resection boundaries, since a second small primary could change the segment requiring treatment and the vascular preservation plan.
Common pitfall: Removing only the imaged lesion can leave multifocal primaries. Visual inspection alone may miss small submucosal tumours that are more readily identified through careful palpation.
NANETS Consensus Guidelines on Surgical Management of Small Bowel Neuroendocrine Tumors — 2017
45.How does mesenteric fibrosis complicate small-bowel NET surgery?
Mesenteric nodal disease and its associated desmoplastic reaction can tether bowel, narrow vessels and produce obstruction or intestinal ischaemia. Operative difficulty depends on the relationship to major mesenteric vessels rather than nodal size alone. Resection must balance disease control against preservation of perfused bowel and avoidance of short-bowel syndrome. Extensive central vascular encasement may justify specialist assessment and a modified operation rather than an attempt to remove every visible deposit at any cost.
Apply it
A patient with an ileal NET develops postprandial pain and has a fibrotic mesenteric mass surrounding major vessels. Assess vascular involvement and bowel viability, then plan surgery in a specialist setting with preservation of intestinal blood supply central to the decision.
Common pitfall: Treating mesenteric disease as an ordinary removable lymph node underestimates vascular risk. Aggressive clearance that sacrifices excessive bowel can create greater harm than residual central disease.
NANETS Consensus Guidelines on Surgical Management of Small Bowel Neuroendocrine Tumors — 2017
46.Why do midgut NETs often cause carcinoid syndrome after liver metastasis?
Hormones released by an intestinal primary usually enter portal blood and undergo hepatic metabolism before reaching the systemic circulation. Liver metastases can release these mediators into hepatic venous blood, bypassing that first-pass clearance and enabling flushing, secretory diarrhoea and other carcinoid manifestations. This pattern has exceptions when venous drainage bypasses the portal liver. Urinary or plasma 5-HIAA, interpreted with collection and interference precautions, helps assess serotonin production and associated complication risk.
Apply it
A patient with a known ileal NET develops flushing and watery diarrhoea after liver lesions appear. Assess a possible carcinoid syndrome and biochemical serotonin burden while reviewing alternative explanations and the implications for cardiac and perioperative evaluation.
Common pitfall: Flushing alone does not establish carcinoid syndrome. Conversely, absence of liver metastases does not make the syndrome impossible when tumour drainage bypasses normal hepatic clearance.
ENETS 2022 Guidance Paper for Carcinoid Syndrome and Carcinoid Heart Disease
47.How should carcinoid heart disease be recognized and assessed?
Sustained serotonin exposure causes plaque-like valvular fibrosis, predominantly affecting the tricuspid and pulmonary valves and producing regurgitation or stenosis with eventual right-heart failure. Significant disease can be clinically silent. Measure baseline NT-proBNP when carcinoid syndrome is diagnosed, and screen patients with elevated 5-HIAA and/or suspicious symptoms at baseline and follow-up. NT-proBNP above 260 pg/mL warrants echocardiography. Suspicious cardiac findings require echocardiographic assessment regardless of the NT-proBNP threshold. Echocardiography defines valve abnormalities and ventricular consequences; the ENETS framework includes baseline echocardiography and surveillance every 6–12 months, with earlier reassessment for clinical deterioration.
Apply it
An asymptomatic patient with newly diagnosed carcinoid syndrome, elevated urinary 5-HIAA and NT-proBNP of 340 pg/mL needs echocardiography despite a normal cardiac examination. Establish baseline valve and right-ventricular findings and arrange surveillance. New oedema, dyspnoea or a murmur should trigger earlier assessment.
Common pitfall: Waiting for overt right-heart failure misses clinically silent valve damage. NT-proBNP below 260 pg/mL makes carcinoid heart disease unlikely but does not override suspicious symptoms or examination findings. Improvement in flushing or diarrhoea does not establish reversal of structural valve fibrosis.
ENETS 2022 Guidance Paper for Carcinoid Syndrome and Carcinoid Heart Disease · J_Neuroendocrinology_-_2022_-_Grozinsky%E2%80%90Glasberg_-_European_Neuroendocrine_Tumor_Society__ENETS__2022_Guidance_Paper_for.pdf
Multiple endocrine neoplasia (MEN)not stated
48.Which combination of endocrine tumours should raise suspicion of MEN1?
MEN1 links parathyroid disease, anterior pituitary tumours and duodenopancreatic neuroendocrine tumours through inherited tumour predisposition. Young age, multigland parathyroid disease, multiple pancreatic lesions or characteristic tumours across relatives strengthen suspicion. Recognizing the syndrome changes surveillance, family counselling and operative expectations. The relevant clinical task is to connect apparently separate endocrine diagnoses rather than treating each lesion as an isolated sporadic event. Germline assessment requires informed counselling and interpretation within the family and phenotype.
Apply it
A young adult with primary hyperparathyroidism is found to have multiple pancreatic NETs and reports a relative with a pituitary tumour. Assess for MEN1 and coordinate genetic counselling and syndrome-specific evaluation before finalizing an isolated organ-based treatment plan.
Common pitfall: Waiting for all classic tumour types to occur delays recognition. A single convincing syndrome pattern can justify assessment even when the family history is incomplete.
NANETS Consensus Paper on Surgical Management of Pancreatic Neuroendocrine Tumors — 2020 · UEMS EBSQ Endocrine Surgery Syllabus V05
49.Which initial parathyroid operation is recommended for MEN1-associated primary hyperparathyroidism, and why?
MEN1-associated primary hyperparathyroidism usually reflects multigland disease, even when imaging identifies only one dominant lesion. AAES recommendation 9-1 recommends subtotal parathyroidectomy as the index operation. This usually removes three glands and part of the fourth, preserving a viable, vascularized remnant to maintain endogenous PTH secretion. Bilateral exploration permits assessment of the glands rather than treating the scan as proof of single-gland disease. The strategy balances control of hypercalcaemia against permanent hypoparathyroidism; retained tissue can subsequently become hyperfunctional.
Apply it
For a patient with confirmed MEN1, hypercalcaemia and one strongly localized lesion, propose bilateral exploration with subtotal parathyroidectomy rather than excision of only the localized gland. Explain that removing the dominant gland alone can leave other abnormal glands untreated and increase the likelihood of persistent or recurrent disease. Preserve functioning parathyroid tissue with an intact blood supply, and discuss postoperative calcium monitoring, possible supplementation and lifelong biochemical surveillance.
Common pitfall: Neither a solitary imaging target nor an initially successful calcium result eliminates the MEN1 multigland mechanism. Leaving more tissue increases the opportunity for future hyperfunction, whereas excessive removal or devascularization increases permanent hypoparathyroidism risk. Subtotal parathyroidectomy addresses this tradeoff but cannot guarantee freedom from recurrence or future reoperation.
AAES Guidelines for Definitive Management of Primary Hyperparathyroidism — 2016 · NANETS Consensus Paper on Surgical Management of Pancreatic Neuroendocrine Tumors — 2020
50.How should pancreatic NET surgery be individualized in MEN1?
MEN1 often produces multiple duodenopancreatic NETs over time, making removal of every visible lesion neither straightforward nor necessarily beneficial. Decisions integrate functional syndrome, lesion size, growth, grade, location and the morbidity of pancreatic resection. Selected small nonfunctioning lesions can be monitored, while clinically important functioning tumours or concerning progression may support intervention. Preserving endocrine and exocrine pancreatic function matters because future lesions and repeat treatment remain possible. Syndrome recognition therefore changes both the operative goal and surveillance plan.
Apply it
A patient with MEN1 has several small stable nonfunctioning pancreatic NETs without concerning structural features. Discuss surveillance and predefined intervention triggers rather than proposing total pancreatectomy solely to eliminate every currently visible lesion from the imaging study.
Common pitfall: Multiplicity does not automatically justify removing the whole pancreas. A lesion-by-lesion plan must still account for dangerous hormone syndromes, growth and evidence of aggressive disease.
NANETS Consensus Paper on Surgical Management of Pancreatic Neuroendocrine Tumors — 2020
51.How does a pathogenic RET variant guide preventive thyroid surgery?
ATA categories distinguish highest risk, high risk and moderate risk. RET M918T is highest risk and warrants thyroidectomy during the first year, potentially the first months. High-risk variants, including codon 634 variants and A883F, warrant thyroidectomy at age 5 or earlier when calcitonin is elevated. Moderate-risk carriers can use monitored calcitonin-directed timing, with examination, neck ultrasound and calcitonin assessment beginning around age 5. Such surveillance requires reliable follow-up and specialist oversight. Family counselling must address surgical risks, lifelong thyroid replacement and the consequences of delay.
Apply it
An infant with RET M918T needs prompt specialist planning for thyroidectomy in infancy rather than waiting for a nodule. A child with a high-risk codon 634 variant needs surgery at age 5 or earlier with elevated calcitonin. Moderate-risk timing may be individualized through reliable monitoring.
Common pitfall: A normal neck examination does not justify delaying M918T surgery. Calcitonin-directed observation in moderate-risk disease must not be generalized to every RET category.
52.Which tumour should be treated first when MEN2 includes pheochromocytoma?
When pheochromocytoma coexists with medullary thyroid carcinoma or hyperparathyroidism, the catecholamine-producing tumour is generally treated first after appropriate preparation. Anaesthesia and surgery for another lesion can provoke a life-threatening catecholamine crisis if pheochromocytoma is unrecognized or untreated. The sequence therefore addresses immediate physiological danger before the other endocrine operation. Biochemical screening for pheochromocytoma is essential before thyroid surgery in established MEN2 and when hereditary medullary cancer status has not yet been resolved.
Apply it
A patient with MEN2 has operable medullary thyroid carcinoma and a biochemically active adrenal pheochromocytoma. Arrange adrenergic preparation and adrenal treatment before the thyroid operation, coordinating both stages so that cancer management proceeds safely after catecholamine risk is controlled.
Common pitfall: Prioritizing the thyroid cancer simply because it is malignant overlooks the acute anaesthetic hazard. Absence of classic spells does not safely exclude a functioning pheochromocytoma.
Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma — 2015 · Pheochromocytoma and Paraganglioma: Endocrine Society Clinical Practice Guideline — 2014
Pituitarynot stated
53.What is the preferred initial definitive treatment for operable pituitary Cushing disease?
Cushing disease is cortisol excess driven by an ACTH-secreting pituitary tumour. When feasible, selective transsphenoidal tumour resection by an experienced pituitary surgeon is the preferred initial definitive treatment. It targets the cause while aiming to preserve normal pituitary function. The diagnosis and source of ACTH excess must be established before treatment because an incidental pituitary lesion does not prove causation. Comorbidities such as diabetes, hypertension, infection and thrombotic risk also require active perioperative management.
Apply it
A patient has confirmed pituitary ACTH-dependent Cushing disease and a surgically accessible lesion. Discuss specialist transsphenoidal surgery and optimization of cortisol-related comorbidities rather than selecting an adrenal operation solely because the adrenal glands produce the excess cortisol.
Common pitfall: Confusing the site of cortisol synthesis with the primary disease source leads to inappropriate initial treatment. A pituitary incidentaloma alone is insufficient evidence for Cushing disease.
Treatment of Cushing's Syndrome: Endocrine Society Guideline Resources — 2015
54.Why can successful pituitary Cushing surgery cause temporary adrenal insufficiency?
Chronic cortisol excess suppresses normal hypothalamic and pituitary drive outside the tumour. Successful removal of the ACTH source can therefore leave insufficient normal ACTH secretion and reduced adrenal reserve during recovery. Low postoperative cortisol can support remission but also creates a need for glucocorticoid replacement and adrenal-insufficiency education. Replacement is withdrawn only after appropriate assessment of axis recovery. Symptoms of glucocorticoid withdrawal can overlap with adrenal insufficiency, so biochemical and clinical evaluation must be integrated.
Apply it
After apparently successful pituitary surgery, a patient has low morning cortisol and asks to avoid steroid replacement. Explain the suppressed normal axis, provide replacement and illness instructions, and arrange reassessment before deciding when treatment can safely be discontinued.
Common pitfall: Interpreting postoperative low cortisol only as a favourable tumour result misses an immediate replacement need. Persistent fatigue alone also cannot determine whether the axis has recovered.
Treatment of Cushing's Syndrome: Endocrine Society Guideline Resources — 2015
55.How should hyperprolactinaemia be evaluated, and when can surgery be an initial prolactinoma treatment?
Dopamine inhibits lactotroph secretion through D2 receptors, so dopamine-blocking drugs or stalk disruption can raise prolactin without a prolactinoma. Assess pregnancy, medications, hypothyroidism and renal impairment. Consider macroprolactin when biochemical elevation and symptoms are discordant, and request sample dilution for a large tumour with unexpectedly modest prolactin to exclude the hook effect. Cabergoline is the preferred dopamine agonist because it effectively lowers prolactin and shrinks tumours. The 2023 Pituitary Society consensus also recommends discussing expert transsphenoidal surgery alongside dopamine agonists as an initial option for microprolactinomas and well-circumscribed macroprolactinomas with Knosp grade 0–1.
Apply it
After confirming a symptomatic microprolactinoma in a patient with amenorrhoea, discuss both cabergoline and surgery by an experienced pituitary surgeon. Compare medical control and tumour shrinkage, medication tolerability and monitoring with the possibility of surgical remission and operative complications, including new pituitary deficits. A well-circumscribed Knosp grade 0–1 macroprolactinoma also merits this initial comparison. When invasion makes surgical remission unlikely, medical treatment remains preferred. Surgery is additionally considered for dopamine agonist intolerance or resistance.
Common pitfall: Raised prolactin plus a pituitary mass does not automatically establish a prolactinoma. Conversely, surgery need not wait for medication failure in anatomically favourable tumours. The initial choice depends on tumour anatomy, expert surgical outcomes and informed patient preference; neither treatment guarantees permanent remission, and biochemical follow-up remains necessary.
UEMS EBSQ Endocrine Surgery Syllabus V05 · prolactinoma_pit_soc_guidelines_2023.pdf
56.How do contemporary acromegaly diagnostic criteria guide assessment and initial treatment?
GH excess increases IGF-1 production and causes acral and soft-tissue overgrowth. The 2024 diagnostic consensus states that characteristic clinical findings together with IGF-1 above 1.3 times the age-adjusted upper limit of normal confirm acromegaly; random GH is not required. For equivocal results, repeat IGF-1 using the same validated assay and consider oral glucose tolerance testing. The historical 2014 guideline used failure to suppress GH below 1 microgram/L during glucose testing as confirmation. This threshold requires its historical and assay context: contemporary interpretation considers assay performance, BMI and clinical findings rather than applying one universal GH cutoff.
Apply it
A patient with progressive hand enlargement and characteristic facial changes has IGF-1 of 420 ng/mL against an age-adjusted upper limit of 300 ng/mL. The ratio is 1.4, meeting the contemporary clinical-biochemical criterion. Obtain pituitary MRI and assess pituitary function, sleep apnoea and cardiovascular comorbidity. An isolated IGF-1 ratio of 1.1 with uncertain clinical findings instead warrants repeat measurement with the same assay and consideration of glucose suppression testing. Transsphenoidal surgery is primary treatment for most operable pituitary tumours; persistent disease or unsuitable surgical anatomy may require medical treatment.
Common pitfall: An incidental pituitary lesion does not prove GH excess, and a single random GH value cannot reliably exclude acromegaly because secretion is pulsatile. Nutrition, hepatic disease, metabolic disturbances and oral oestrogen can alter biochemical interpretation. No glucose-suppressed GH cutoff definitively excludes every case. Apparent complete tumour removal also requires postoperative biochemical assessment; IGF-1 at approximately 12 weeks helps assess remission.
UEMS EBSQ Endocrine Surgery Syllabus V05 · acromegalialg.pdf · 11102_2023_Article_1360.pdf
Scientific-paper appraisalnot stated
57.How do relative and absolute treatment effects differ?
A relative effect compares event probabilities proportionally, whereas an absolute effect describes the difference in event probability. If complications fall from 10% to 5%, the relative risk is 0.5 and the absolute risk reduction is 5 percentage points. The same relative effect produces a smaller absolute benefit when baseline risk is lower. Interpretation therefore requires the control risk, follow-up period and outcome definition, rather than a headline relative reduction detached from the clinical setting.
Apply it
A surgical paper reports a 50% relative reduction in complications. Calculate the absolute effect using its control event rate, then ask whether your patients have similar baseline risk before presenting the expected benefit during a treatment discussion.
Common pitfall: A percentage reduction and a percentage-point reduction are different quantities. Applying a relative effect without baseline risk can substantially exaggerate the benefit a patient expects.
Cochrane Handbook, Chapter 15: Interpreting Results and Drawing Conclusions
58.What does a confidence interval reveal beyond statistical significance?
A confidence interval describes the precision of an estimated effect under the analysis assumptions. For a risk ratio, the null is 1; for a risk difference, it is 0. An interval crossing the null does not prove equivalence or absence of a clinically important effect. Examine whether the interval includes meaningful benefit and harm, then consider sample size, bias and outcome importance. Statistical significance alone cannot establish that an effect is sufficiently large to matter clinically.
Apply it
A trial reports a complication risk ratio of 0.85 with a 95% confidence interval of 0.45–1.60. Explain that substantial benefit and harm remain compatible with the estimate, rather than concluding that the procedures have equivalent complication rates.
Common pitfall: Calling a nonsignificant result proof of no difference confuses uncertainty with equivalence. A narrow interval around a trivial effect can also be statistically significant without clinical importance.
Cochrane Handbook, Chapter 15: Interpreting Results and Drawing Conclusions
59.How is number needed to treat calculated and bounded?
Number needed to treat is the reciprocal of the absolute risk reduction expressed as a proportion. Reducing an event rate from 12% to 8% gives an absolute reduction of 0.04 and an NNT of 25 over the study's follow-up. The estimate applies to the specified outcome, population and period, and should be considered alongside uncertainty and harms. If the confidence interval for the absolute effect crosses zero, the corresponding NNT interpretation becomes discontinuous and requires care.
Apply it
A trial reports 12 postoperative complications per 100 control patients and 8 per 100 treated patients over one year. Calculate an NNT of 25 for preventing one such complication over that year, then consider treatment-related harms separately.
Common pitfall: Using the reciprocal of a relative reduction gives the wrong NNT. Reporting NNT without its outcome and time horizon makes comparisons between interventions potentially misleading.
Cochrane Handbook, Chapter 15: Interpreting Results and Drawing Conclusions
60.How should surgical study applicability and confounding be judged?
A study informs practice only when its population, interventions, expertise, outcomes and follow-up address the clinical decision at hand. In observational surgical comparisons, healthier patients, smaller tumours or specialist-centre access may influence both treatment selection and outcomes. Statistical adjustment reduces only measured confounding under its assumptions; it does not recreate randomization. Appraisal should separate the observed association from a causal claim and examine absolute benefits, harms, patient priorities and whether local expertise matches the study setting.
Apply it
A retrospective series shows better survival after surgery, but operated patients were younger and had less metastatic disease. Identify selection and confounding before recommending surgery to a frail patient with extensive disease who differs substantially from the reported surgical cohort.
Common pitfall: A large adjusted association is not automatically causal. Equally, methodological limitations do not make a study useless; they determine how cautiously its findings should influence decisions.
Cochrane Handbook, Chapter 15: Interpreting Results and Drawing Conclusions
What to focus on during revision
The following are CertMedbry study suggestions. Use the official outline to check the full scope of your examination.
- Explain hormone feedback before choosing imaging: suppressed TSH, inappropriate PTH, renin suppression and autonomous cortisol each change the pathway.
- Separate biochemical diagnosis, anatomical localization, staging and operative indication; identify what each investigation can and cannot establish.
- Defend surgical extent using disease biology, multigland risk, invasion, nodal compartments and preservation of organ function.
- Rehearse immediate responses to neck haematoma, catecholamine risk, hypocalcaemia and postoperative adrenal insufficiency.
- Connect MEN recognition with family assessment, multigland planning, preventive surgery and safe operative sequencing.
- Interpret the two assigned papers using absolute effects, confidence intervals, bias, applicability and patient-important outcomes.
- Use the official full syllabus to cover unselected subjects, including Graves disease and thyroid-storm preparation, additional thyroid operations, renal parathyroid operative indications and procedures, communication, teamwork and management.
A practical preparation plan
1. Map the full pathway
Read Syllabus V05 alongside Curriculum V04. Build a domain checklist and distinguish factual knowledge from the clinical and professional activities you must explain and demonstrate. Use the official documents to identify gaps beyond these 60 selected concepts.
2. Build biochemical decision chains
For each hormone syndrome, write the expected feedback response, the abnormal pattern, important confounders and the next justified test. Practise explaining why localization follows biochemical confirmation rather than replacing it.
3. Practise case discussions aloud
Present diagnosis, immediate risk, further assessment, treatment options, operative extent and follow-up in a coherent sequence. Include how you would communicate uncertainty, obtain consent and coordinate endocrinology, anaesthesia, pathology and other relevant teams.
4. Use the drills diagnostically
Complete the 20 questions before reading their explanations. For every error, identify the missed discriminator and explain why each alternative is less appropriate. Revisit the corresponding concept and use the flashcards to test the underlying principle.
5. Prepare each scientific paper
Summarize the clinical question, design, population, comparator, outcomes and follow-up. Calculate an absolute effect when possible, inspect confidence intervals, identify likely bias and decide whether the findings change care for a specified patient.
6. Rehearse the examination format
Arrange two 50–60 minute English-language oral practice sessions covering clinical cases, contextual basic science and paper appraisal. Ask colleagues to challenge your operative choices and complication plans, then use their feedback to target remaining syllabus gaps.
Use your sample score as a starting point
The free set contains 20 original practice questions. It is a small learning sample, not an official examination or a validated pass prediction. Review each explanation and its source before moving to another topic.
Start the free sampleOfficial sources and updates
- Endocrine Surgery EBSQ Examinations
- Endocrine Surgery — UEMS Section of Surgery
- Endocrine Surgery Syllabus and Curriculum
- UEMS EBSQ Endocrine Surgery Syllabus V05
- UEMS EBSQ Endocrine Surgery Curriculum V04
- UEMS EBSQ Endocrine Surgery Syllabus V04 — historical version
- 2023 European Thyroid Association Clinical Practice Guidelines for Thyroid Nodule Management
- 2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer
- Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma — 2015
- Management of Haematoma Following Thyroid Surgery — Supporting Materials Version 1.0
- Evaluation and Management of Primary Hyperparathyroidism: Fifth International Workshop Guidelines — 2022
- AAES Guidelines for Definitive Management of Primary Hyperparathyroidism — 2016
- European Expert Consensus on Parathyroid Disorders: PARAT 2021 — published 2022
- ESE Clinical Practice Guidelines on Adrenal Incidentalomas — 2023
- Primary Aldosteronism: An Endocrine Society Clinical Practice Guideline — 2025
- Pheochromocytoma and Paraganglioma: Endocrine Society Clinical Practice Guideline — 2014
- AAES Guidelines for Adrenalectomy: Executive Summary — 2022
- NANETS Consensus Paper on Surgical Management of Pancreatic Neuroendocrine Tumors — 2020
- ENETS 2023 Guidance Paper for Functioning Pancreatic Neuroendocrine Tumour Syndromes
- NANETS Consensus Guidelines on Surgical Management of Small Bowel Neuroendocrine Tumors — 2017
- ENETS 2022 Guidance Paper for Carcinoid Syndrome and Carcinoid Heart Disease
- Treatment of Cushing's Syndrome: Endocrine Society Guideline Resources — 2015
- Cochrane Handbook, Chapter 15: Interpreting Results and Drawing Conclusions
- Bilezikian-2022-Evaluation-and-management-of-primar.pdf
- European expert consensus on practical management of specific aspects of parathyroid disorders in adults and in pregnancy: recommendations of the ESE Educational Program of Parathyroid Disorders (PARAT 2021) - PMC
- J_Neuroendocrinology_-_2022_-_Grozinsky%E2%80%90Glasberg_-_European_Neuroendocrine_Tumor_Society__ENETS__2022_Guidance_Paper_for.pdf
- prolactinoma_pit_soc_guidelines_2023.pdf
- acromegalialg.pdf
- 11102_2023_Article_1360.pdf
- thyroid_cancer_ata_2025.pdf
Confirm current eligibility, fees, scheduling and policies directly with the examination provider. CertMedbry is independent and is not endorsed by these organisations. How we handle content and corrections.